首页> 美国卫生研究院文献>Journal of Clinical and Diagnostic Research : JCDR >Clinical Utility of Fractional exhaled Nitric Oxide (FeNO) as a Biomarker to Predict Severity of Disease and Response to Inhaled Corticosteroid (ICS) in Asthma Patients
【2h】

Clinical Utility of Fractional exhaled Nitric Oxide (FeNO) as a Biomarker to Predict Severity of Disease and Response to Inhaled Corticosteroid (ICS) in Asthma Patients

机译:分数呼出气一氧化氮(FeNO)作为生物标志物预测哮喘患者的疾病严重程度和对吸入皮质类固醇(ICS)反应的临床效用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

IntroductionBronchial asthma is a common chronic inflammatory airway disease diagnosed and is based on symptomatic history and Pulmonary Function Tests (PFT). Fractional exhaled Nitric Oxide (FeNO) is exclusively a non-invasive biomarker of on-going eosinophilic airway inflammation which remains unpredictable only with PFTs. FeNO measurement is recommended in predicting asthma severity and Inhaled Corticosteroid (ICS) response but further research is required to understand its clinical utility and agreement with current recommendations in a specific population.
机译:简介支气管哮喘是一种经诊断的常见慢性炎症性气道疾病,基于症状史和肺功能检查(PFT)。呼出气一氧化氮(FeNO)仅是持续的嗜酸性气道炎症的非侵入性生物标志物,仅使用PFT仍无法预测。建议使用FeNO测量来预测哮喘的严重程度和吸入皮质类固醇(ICS)反应,但需要进一步的研究以了解其临床实用性并与特定人群中的当前建议相一致。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号